December 11, 2025 - Medtronic plc, a global leader in healthcare technology, today announced new data demonstrating the significant health economic benefits of the MiniMed™ 780G advanced hybrid closed-loop system over the standard of care using multiple daily injections (MDI) with intermittently scanned continuous glucose monitoring (isCGM).

2025年12月11日，全球医疗技术领导者美敦力公司今天宣布了新的数据，表明与使用间歇扫描连续血糖监测（isCGM）的每日多次注射（MDI）标准治疗相比，MiniMed™ 780G高级混合闭环系统具有显著的健康经济效益。

With the prevalence of diabetes in the Western Pacific region.

随着西太平洋地区糖尿病的流行。

i

我

predicted to rise from 12.4% today to 14.7% by 2050, these findings underscore the growing value of automated insulin delivery systems in managing type 1 diabetes across diverse care settings. The evidence was presented at the Advanced Technologies & Treatments for Diabetes ATTD Asia 2025, the 2nd Asian Conference on Innovative Therapies for Diabetes Management.  .

预计到2050年，这一比例将从今天的12.4%上升到14.7%。这些研究结果突显了自动化胰岛素输送系统在不同护理环境中管理1型糖尿病的日益增长的价值。该证据在2025年ATTD亚洲大会（第2届亚洲糖尿病管理创新疗法会议）上发布。

Consistent benefits across Asia-Pacific

亚太地区的一致利益

Three independent studies from Japan, Hong Kong and Australia showed that the MiniMed™ 780G system consistently demonstrated improved quality of life and reduced the long-term risk of diabetes-related complications compared to MDI+isCGM. These clinical advantages generated meaningful cost savings that partially offset the system’s higher upfront costs..

来自日本、香港和澳大利亚的三项独立研究表明，与MDI+isCGM相比，MiniMed™ 780G系统持续表现出生活质量的提升，并降低了糖尿病相关并发症的长期风险。这些临床优势带来了显著的成本节约，部分抵消了该系统较高的前期成本。

Hong Kong

香港

ii

二

+2.351 quality-adjusted life-years (QALYs)

+2.351质量调整生命年（QALYs）

HKD 306,179 savings per person, from reduced complications

每人因并发症减少而节省306,179港元

Incremental cost-effectiveness ratio (ICER): HKD 392,602 per QALY-gained

增量成本效益比 (ICER)：每获得一个质量调整生命年 (QALY) 为 392,602 港元

Japan

日本

iii

iii

+2.865 QALYs.

+2.865 质量调整生命年。

¥2,857,914 savings per person, from reduced complications

每人因减少并发症而节省¥2,857,914

ICER: ¥4,423,282 per QALY-gained

ICER：每获得一个质量调整生命年（QALY）为¥4,423,282

Australia

澳大利亚

iv

四

+1.403 QALYs

+1.403 质量调整生命年

AUD 47,792 in savings per person, from reduced complications

每人因减少并发症而节省 47,792 澳元

ICER: AUD 32,734 per QALY-gained

ICER：每获得一个QALY的成本为32,734澳元

In all three countries, the focus was on adults with sub-optimally controlled type 1 diabetes (HbA1c >8%). All analyses leveraged data from the peer reviewed ADAPT study,

在所有三个国家中，研究重点都是血糖控制欠佳（HbA1c >8%）的成年 1 型糖尿病患者。所有分析都利用了经过同行评审的 ADAPT 研究中的数据，

v

v

which found a 1.54% reduction in HbA1c with the MiniMed™ 780G system, compared to a 0.2% reduction with MDI+isCGM from a baseline of 9.00% and 9.07%, respectively.

研究发现，使用MiniMed™ 780G系统后，HbA1c水平降低了1.54%，而使用MDI+isCGM仅降低了0.2%，两者的基线值分别为9.00%和9.07%。

Baseline characteristics, complication costs, and quality of life measures were sourced from local publications where possible. A lifetime horizon was used, reflecting the expected duration of living with T1D based on country-specific factors, and local willingness-to-pay thresholds were applied to determine cost-effectiveness..

基线特征、并发症成本和生活质量指标尽可能取自当地出版物。使用了终身时间范围，反映了基于特定国家因素的1型糖尿病（T1D）预期持续时间，并应用当地的支付意愿阈值来确定成本效益。

“Greater accessibility and education on the benefits of hybrid closed loop therapy today will translate into healthier lives and lower costs tomorrow.” said Prof. Sarah Glastras, Consultant Endocrinologist at the Northern Sydney Endocrine Centre in Australia.

“如今，让更多人了解混合闭环疗法的好处并进行相关教育，明天就会转化为更健康的生活和更低的成本。”澳大利亚北悉尼内分泌中心的顾问内分泌学家莎拉·格拉斯特拉斯教授说道。

Strong alignment with global economic evidence:

与全球经济证据高度一致：

These robust results from the Asia-Pacific region follow similar recent health economic evidence in Europe that demonstrates how the adoption of automated insulin delivery (AID) systems can potentially reduce the long-term costs and burden of diabetes for individuals, healthcare systems and society..

这些来自亚太地区的有力结果与欧洲近期类似的健康经济学证据相符，证明了采用自动胰岛素输送（AID）系统可能减少个人、医疗系统和社会的糖尿病长期成本和负担。

A cost-utility analysis

成本效用分析

vi

vi

across six European countries found that the MiniMed™ 780G system delivers up to three extra years free of complications and greater quality adjusted life-expectancy that corresponds to 829 days of full health, and average savings of €32,000* per person in long-term complications avoided.

跨越六个欧洲国家的研究发现，MiniMed™ 780G 系统可提供长达三年的无并发症时间，并带来更高的质量调整寿命，相当于829天的完全健康状态，平均每人因避免长期并发症而节省32,000欧元*。

A 2025 UK study

2025年英国研究

vii

七

found that increasing time in range (TIR) by 10 percentage points would reduce long-term complication costs by 7.5%-9.9% over 20 years for the NHS.

发现将范围内时间（TIR）增加10个百分点，可使NHS在20年内减少7.5%-9.9%的长期并发症费用。

A study in France

法国的一项研究

viii

八

showed the MiniMed™ 780G system led to an extra 2.89 years free of any long-term complications compared with MDI+isCGM.

结果显示，与MDI+isCGM相比，MiniMed™ 780G系统可额外延长2.89年无任何长期并发症的时间。

“Data like this reminds us why innovation matters,” said Que Dallara, president of Medtronic Diabetes. “When people living with diabetes have access to technology that works with them, everyone benefits — individuals, families, and health systems alike. The results from these independent studies across the Asia-Pacific reinforce what we’ve seen globally: the MiniMed™ 780G system makes diabetes more predictable so people can live with greater freedom and better health.”.

“这样的数据提醒我们创新为何重要，”美敦力糖尿病业务总裁奎·达拉拉表示。“当糖尿病患者能够获得与之配合的技术时，所有人都能受益——个人、家庭以及卫生系统皆是如此。这些在亚太地区进行的独立研究的结果证实了我们在全球范围内所看到的情况：MiniMed™ 780G 系统使糖尿病更可预测，因此人们可以生活得更加自由、健康。”

A call for broader access to proven technologies

呼吁更广泛地获取经过验证的技术

According to the International Diabetes Federation (IDF), diabetes-related expenditure in the Western Pacific region totaled $246 billion

根据国际糖尿病联合会 (IDF) 的数据，西太平洋地区的糖尿病相关支出总计达 2460 亿美元

i

我

in 2024, the second highest of all IDF regions and 24% of global diabetes expenditure. Despite a decade of progress in Automated Insulin Delivery (AID) systems and strong clinical and real-world evidence showing their superiority over MDI+isCGM, access remains inequitable — especially across developing economies.

2024年， IDF所有地区中第二高，占全球糖尿病支出的24%。尽管自动胰岛素输送（AID）系统在十年内取得了进展，并且有强有力的临床和真实世界证据表明其优于MDI+isCGM，但获取途径仍然不平等，尤其是在发展中国家经济体中。

A 2025 Call-to-Action.

2025年行动号召。

ix

九

coalition of leading clinicians and academics urges professional societies and government agencies to recognize AID systems as standard of care for glycemic management in youth and adults with T1D, and to integrate these recommendations into current and future guidelines to close the gap in access:.

由知名临床医生和学者组成的联盟敦促专业协会和政府机构将AID系统认定为T1D青少年和成人血糖管理的标准护理，并将这些建议纳入当前和未来的指南中，以缩小获取途径的差距。

All people with type 1 diabetes and other patients with insulin-dependent diabetes must be given a choice to use an AID system at the time of diagnosis or as soon after diagnosis as possible.

所有1型糖尿病患者以及其他胰岛素依赖型糖尿病患者必须在诊断时或尽可能接近诊断后的时间内获得使用AID系统的选择。

The reason(s) for not giving a choice of using an AID system should be documented in the medical record.

未提供使用AID系统的选择的原因应记录在病历中。

The choice of device should be made based on the individual’s circumstances, preferences, and needs.

设备的选择应根据个人的情况、偏好和需求来决定。

National health care systems should prioritize the provision of unfettered access to AID systems to democratize the known benefits of AID systems.

国家医疗保健系统应优先提供对AID系统的无限制访问，以普及AID系统的已知益处。

Frequently Asked Questions

常见问题解答

Q: What is the MiniMed™ 780G system?

问：MiniMed™ 780G系统是什么？

The MiniMed™ 780G system is the most advanced insulin pump system from Medtronic. The MiniMed™ 780G system's SmartGuard™ algorithm (also referred to as the advanced hybrid closed-loop algorithm) automates the delivery of insulin every five minutes — personalizing these doses to auto-correct

MiniMed™ 780G 系统是美敦力最先进的胰岛素泵系统。MiniMed™ 780G 系统的 SmartGuard™ 算法（也称为高级混合闭环算法）每五分钟自动输送胰岛素——个性化这些剂量以实现自动校正。

†

†

highs every five minutes based on CGM readings.

每五分钟根据CGM读数记录高点。

§

§

The system is designed to be used at a target glucose of 100 mg/dl (5.5 mmol/L) that can be adjusted and personalized on an individual basis. It is intended for people with type 1 and type 2 diabetes who require insulin and who are seeking more automation and easier management of their diabetes therapy..

该系统设计用于目标血糖值为 100 mg/dl（5.5 mmol/L），可以根据个体情况调整和个性化设置。适用于需要胰岛素的 1 型和 2 型糖尿病患者，他们希望通过更多自动化和更简便的方式来管理糖尿病治疗。

Q.: What is payer-focused analysis?

问：什么是付款人聚焦分析？

Payer-focused analysis evaluates healthcare interventions from the perspective of those who fund or reimburse care—such as government agencies, insurance companies, or other payers. In the context of the MiniMed™ 780G studies, this approach examines the cost-effectiveness and budget impact of adopting the advanced diabetes technology.

以支付方为中心的分析从为医疗保健干预提供资金或报销的机构（如政府机构、保险公司或其他支付方）的角度进行评估。在 MiniMed™ 780G 研究的背景下，这种方法审查了采用先进糖尿病技术的成本效益和预算影响。

It considers long-term cost savings, improvements in quality-adjusted life-years (QALYs), and reductions in diabetes-related complications compared to standard care. The goal is to provide decision-makers with clear evidence on the value and cost-effectiveness of medical interventions, supporting efficient resource allocation within the healthcare system..

它考虑了与标准护理相比的长期成本节约、质量调整生命年（QALYs）的提升以及糖尿病相关并发症的减少。目标是为决策者提供关于医疗干预措施的价值和成本效益的明确证据，支持医疗系统内的资源有效分配。

Q: What is a Quality Adjusted Life Year (QALY)?

问：什么是质量调整生命年（QALY）？

QALY (Quality-Adjusted Life Year) is a health economics metric that measures the value of medical interventions by combining life expectancy and quality of life. One QALY equals one year in perfect health; lower health quality reduces the value proportionally (e.g., 0.7 QALYs for a year at 70% health).

质量调整生命年（QALY）是健康经济学中的一种指标，它通过结合预期寿命和生活质量来衡量医疗干预的价值。一个QALY等于完全健康状态下的一年；健康质量较低时，其价值会按比例降低（例如，70%健康状态的一年相当于0.7个QALY）。

QALYs are calculated by multiplying years gained by a quality-of-life weight (0–1). This metric enables comparison of treatment effectiveness and supports cost-effectiveness analyses for resource allocation..

质量调整生命年 (QALY) 通过将获得的寿命年数乘以生活质量权重（0-1）来计算。该指标能够比较治疗效果，并支持用于资源分配的成本效益分析。

Q. What is Quality-Adjusted Life Expectancy (QALE)?

问：什么是质量调整生命期望（QALE）？

This is a summary measure in health economics and outcomes research. It represents the expected number of years of life remaining, adjusted for the quality of those years based on health status. QALE is calculated by multiplying the remaining years of life by the average utility value for those years and is used to compare the overall health status or burden of disease across populations or to estimate the impact of interventions on a person’s or population’s expected future health..

这是健康经济学和结果研究中的一个综合指标。它表示根据健康状况调整后的预期剩余寿命年数。QALE通过将剩余寿命年数乘以这些年份的平均效用值来计算，用于比较不同人群的整体健康状况或疾病负担，或估算干预措施对个人或人群未来预期健康的影响。

Q: What is the incremental cost-effectiveness ratio (ICER)?

问：什么是增量成本效益比 (ICER)？

The incremental cost-effectiveness ratio (ICER) compares two health interventions by dividing the difference in costs by the difference in effectiveness, usually in QALYs. It shows the extra cost required for one additional unit of health benefit, helping policymakers judge if a new treatment’s benefits justify its added cost..

增量成本效益比 (ICER) 通过将两种健康干预措施的成本差异除以效果差异（通常以质量调整生命年 (QALY) 计算）来进行比较。它显示了获得一个额外单位健康收益所需的额外成本，帮助决策者判断新治疗的益处是否值得其增加的成本。

Q: What is the willingness-to-pay (WTP) threshold?

问：支付意愿（WTP）阈值是什么？

The willingness-to-pay (WTP) threshold is the maximum cost society, payers, or individuals accept for one unit of health benefit, typically a QALY. It guides decisions on whether an intervention’s incremental cost-effectiveness ratio (ICER) falls below this threshold, making it cost-effective and more likely to be adopted.

意愿支付（WTP）阈值是社会、支付方或个人为一个单位的健康效益（通常是一个质量调整生命年，QALY）所接受的最高成本。它指导着对某项干预措施的增量成本效益比（ICER）是否低于该阈值的决策，若低于，则认为其具有成本效益，更有可能被采纳。

WTP thresholds vary by country and health system..

支付意愿门槛因国家和卫生系统而异。

Q: What is the ADAPT study?

问：ADAPT研究是什么？

The Advanced Hybrid Closed Loop Study in Adult Population with Type 1 Diabetes (ADAPT) study was the first prospective, multicenter, open-label randomized control trial (RCT) to evaluate the MiniMed™ 780G AID algorithm versus MDI with isCGM in adults with type 1 diabetes and poor glucose control (HbA1c ≥8.0%).

成人1型糖尿病高级混合闭环研究（ADAPT）是首个前瞻性、多中心、开放标签的随机对照试验（RCT），旨在评估MiniMed™ 780G AID算法与使用isCGM的每日多次注射（MDI）在血糖控制不佳（HbA1c ≥8.0%）的成年1型糖尿病患者中的效果。

v

v

. Over 6 months, AID therapy achieved a 1.4% HbA1c reduction and a 27.6% increase in time in range (70–180 mg/dL) compared to MDI+isCGM.

在6个月内，与MDI+isCGM相比，AID治疗使HbA1c降低了1.4%，并将血糖在目标范围（70-180 mg/dL）内的时间增加了27.6%。

* Cost effectiveness results vary in countries. The potential cost-saving figures provided represent the average of the countries included in the analysis.

* 成本效益结果因国家而异。所提供的潜在成本节约数字代表了分析中包含的国家的平均值。

† Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off.

† 指自动校正，提供大剂量辅助功能。可以无需用户干预自动交付所有自动校正剂量，该功能可以开启和关闭。

§ Refers to SmartGuard™ feature. Individual results may vary.

§ 指的是 SmartGuard™ 功能。个人结果可能有所不同。

About the Diabetes Business at Medtronic

关于美敦力的糖尿病业务

Medtronic Diabetes is on a mission to make diabetes more predictable, so everyone can embrace life to the fullest with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront..

美敦力糖尿病事业部致力于让糖尿病变得更可预测，使每个人都能通过最先进的糖尿病技术和随时随地的支持，充分享受生活。四十多年来，我们率先推出了多项首创的创新技术，并承诺通过下一代传感器（CGM）、智能给药系统以及数据科学和人工智能的力量，设计糖尿病管理的未来，同时始终将客户体验置于首位。

About Medtronic

关于美敦力

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考。更果敢的行动。我们是美敦力。美敦力公司总部位于爱尔兰戈尔韦，是全球领先的医疗技术公司，通过寻找并发现解决方案，大胆攻克人类面临的最严峻健康问题。我们的使命——减轻病痛、恢复健康、延长寿命——团结了遍布150多个国家的95,000多名充满热情的员工。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法治疗70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们多样化的知识、永无止境的好奇心和帮助所有需要帮助的人的愿望，我们提供了创新的技术，每秒、每小时、每一天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit .

随着我们推动以洞察力为导向的护理、以人为本的体验以及为我们的世界带来更好的结果，期待我们做得更多。在我们所做的每一件事中，我们都在创造非凡。欲了解有关美敦力的更多信息，请访问。

www.Medtronic.com

www.美敦力.com

and follow on

并关注

LinkedIn

领英

.

。

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

任何前瞻性陈述都受到风险和不确定性的影响，例如美敦力公司向证券交易委员会提交的定期报告中所述的风险和不确定性。实际结果可能与预期结果有重大差异。

Contacts:

联系人：

Andrew Crawford

安德鲁·克劳福德

Public Relations

公共关系

+41-79-378-1932

+41-79-378-1932

Ryan Weispfenning

瑞安·魏斯芬宁

Investor Relations

投资者关系

+1-763-505-4626

+1-763-505-4626

i

我

International Diabetes Federation Diabetes Atlas. Diabetes Regional Report 2000-2050 Western Pacific region:

国际糖尿病联合会糖尿病地图集。糖尿病区域报告2000-2050西太平洋地区：

https://diabetesatlas.org/data-by-location/region/western-pacific/

https://diabetesatlas.org/data-by-location/region/western-pacific/

ii

二

Chow E., Ozdemir Z, Hill, M, de Portu S. Management of type 1 diabetes in Hong Kong: Cost-effectiveness of MiniMed 780G advanced hybrid closed-loop system versus multiple daily injections with continuous glucose monitoring. 2

周E.，奥兹德米尔Z，希尔M，德波图S。香港地区1型糖尿病管理：MiniMed 780G高级混合闭环系统与多次每日注射结合连续血糖监测的成本效益分析。

nd

nd

Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2025)

亚洲糖尿病管理创新疗法会议（ATTD-ASIA 2025）

iii

iii

Kodani N, Atsuhito T, Ozdemir Z, Hill, M, de Portu S, Hirota Y. A Japanese cost-effectiveness analysis for managing suboptimally controlled type 1 diabetes; MiniMed 780G advanced hybrid closed-loop system versus multiple daily injections with continuous glucose monitoring. 2

小谷仁，厚仁竹，奥兹德米尔Z，希尔M，德波图S，广田Y。日本针对管理控制不佳的1型糖尿病的成本效益分析；MiniMed 780G高级混合闭环系统与多针注射结合连续血糖监测的比较。2

nd

nd

Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2025)

亚洲糖尿病管理创新疗法会议（ATTD-ASIA 2025）

ivv

ivv

Glastras S., Huynh M, Ozdemir Z, Challis G, Hill M, de Portu S. Cost-effectiveness of MiniMed 780G Advanced hybrid closed-loop system versus multiple daily injections with continuous glucose monitoring for managing suboptimally controlled type 1 diabetes in Australia. 2

格拉斯特拉斯 S.，黄 M，奥兹德米尔 Z，查利斯 G，希尔 M，德波图 S。在澳大利亚，使用 MiniMed 780G 先进混合闭环系统与多次每日注射结合连续葡萄糖监测管理控制不佳的1型糖尿病的成本效益分析。2

nd

nd

Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2025)

亚洲糖尿病管理创新疗法会议（ATTD-ASIA 2025）

v

v

Choudhary P, Kolassa R, Keuthage W et al. on behalf of the ADAPT study Group*. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. Lancet Diab 2022; 10:720-731.

Choudhary P、Kolassa R、Keuthage W 等代表 ADAPT 研究组。高级混合闭环治疗与传统治疗在1型糖尿病成人患者中的比较（ADAPT）：一项随机对照研究。《柳叶刀糖尿病》2022；10：720-731。

vi

vi

Jendle J, Buompensiere M.I, Ozdemir Z, de Portu S, Smith-Palmer J, Pollock R, Cohen O. A European Cost-Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 Diabetes.

詹德尔 J、邦彭西埃 M.I、奥兹德米尔 Z、德·波图 S、史密斯-帕尔默 J、波洛克 R、科恩 O。《欧洲成本效用分析：MiniMed™ 780G 先进混合闭环系统与间歇扫描连续葡萄糖监测结合多剂量每日胰岛素注射在1型糖尿病患者中的应用》。

Diabetes Technologies and Therapeutics 2025; 16:2311-2331.  .

糖尿病技术与治疗 2025；16：2311-2331。

https://www.liebertpub.com/doi/10.1089/dia.2023.0297

https://www.liebertpub.com/doi/10.1089/dia.2023.0297

vii

七

Hussain S, Ozdemir Saltik AZ, Yu JJ, de Portu S, Pollock RF, Pöhlmann J, Cohen O. Improving Time-in-Range in Type 1 Diabetes: Projecting the Clinical and Cost Implications of Automated Insulin Delivery. Diabetes Technol Ther. 2025 Sep 19. doi: 10.1177/15209156251380593. Epub ahead of print. PMID: 40968676..

胡赛因 S、奥兹德米尔·萨尔蒂克 AZ、余 JJ、德·波图 S、波洛克 RF、珀尔曼 J、科恩 O。改善1型糖尿病的范围内时间：预测自动胰岛素输送的临床和成本影响。《糖尿病技术与治疗》。2025年9月19日。doi: 10.1177/15209156251380593。提前在线发表。PMID: 40968676。

viii

八

Hanaire H, Ozdemir Saltik AZ, Pollock RF, Nanu N, Sambuc C, Grangeon A, De Portu S, Koch P, Cohen O, Thivolet C. Cost-Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People with Type 1 Diabetes in France.

法国1型糖尿病患者中MiniMed™ 780G高级混合闭环系统与间歇扫描连续葡萄糖监测结合多针胰岛素注射的成本效用分析

Diabetes Technol Ther. 2025 Oct;27(10):768-777. doi: 10.1089/dia.2025.0100. Epub 2025 Jul 2. PMID: 40601565..

糖尿病技术与治疗。2025年10月；27（10）：768-777。doi：10.1089/dia.2025.0100。电子出版日期：2025年7月2日。PMID：40601565。

ix

九

Saboo B et al. A Call-to-Action to Eliminate Barriers to Accessing Automated Insulin Delivery Systems for People with Type 1 Diabetes. Diabetes Technology & Therapeutics Vol 27, No. 3. https://doi.org/10.1089/dia.2025.0028

Saboo B 等。呼吁采取行动消除1型糖尿病患者获取自动胰岛素输送系统的障碍。《糖尿病技术与治疗学》第27卷，第3期。https://doi.org/10.1089/dia.2025.0028

x

x

Choudhary P, et al. Advanced Hybrid Closed Loop Study In An Adult Population With Type 1 diabetes (Adapt): A Randomized Controlled Study. Lancet Diabetes Endocrinol. 2022; 10(10):720-731.

Choudhary P, 等。成人1型糖尿病患者中高级混合闭环系统研究（Adapt）：一项随机对照研究。《柳叶刀糖尿病与内分泌学》。2022年；10(10):720-731。